Rhenman & Partners Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.2M	Buy	560,250 +181,000	+48%	+$3.76M	1.16%	39
2026 Q1	$8.86M	Sell	379,250 -107,750	-22%	-$2.34M	1.09%	37
2025 Q4	$10.2M	Sell	487,000 -87,000	-15%	-$1.52M	0.96%	40
2025 Q3	$8.83M	Hold	574,000	–	–	0.98%	39
2025 Q2	$5.38M	Buy	574,000 +141,000	+33%	+$1.55M	0.68%	47
2025 Q1	$5.32M	Buy	433,000 +201,000	+87%	+$2.84M	0.61%	45
2024 Q4	$3.07M	Sell	232,000 -27,500	-11%	-$471K	0.32%	68
2024 Q3	$5M	Buy	259,500 +31,000	+14%	+$640K	0.41%	64
2024 Q2	$4.69M	Buy	228,500 +50,000	+28%	+$1.05M	0.45%	55
2024 Q1	$4.25M	Buy	+178,500	New	+$3.98M	0.4%	56

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Rhenman & Partners Asset Management's SNDX Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Syndax Pharmaceuticals (SNDX) stake by 48% in Q2 2026, buying an estimated $3.76M and bringing the position to 560,250 shares worth $12.2M. The position accounts for 1.16% of the portfolio, ranked #39.

Rhenman & Partners Asset Management first reported a position in SNDX in Q1 2024 and has held it in 10 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Rhenman & Partners Asset Management held 560,250 shares of Syndax Pharmaceuticals worth $12.2M as of Q2 2026.
Rhenman & Partners Asset Management bought 181,000 Syndax Pharmaceuticals shares in Q2 2026, an estimated $3.76M.
Syndax Pharmaceuticals made up 1.16% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #39 holding.
Rhenman & Partners Asset Management first reported a position in Syndax Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.